Safeguard Scientifics, a Pennsylvania-based investor in information technology and life sciences companies, announced that its portfolio company Clarient has filed a registration statement with the Securities and Exchange Commission on Form S-3 relating to shares of Clarient owned by Safeguard. Safeguard President and CEO Peter J. Boni says that the filing replaces a registration statement that expired last February. Although the filing would give Safeguard the right to sell Clarient stock publicly when the registration takes effect, Boni stated that Safeguard does not intend to trickle out shares of Clarient into the market. Safeguard owns 47 percent of Clarient’s stock. The market value of Safeguard’s position in Clarient was $169 million as of June 19, compared to $76 million at the end of last year.
Clarient, based in Aliso Viejo, Calif., provides comprehensive anatomic pathology and molecular testing services. The company recently launched a new gene mutation test for non-small cell lung cancer, the most common form of lung cancer.
Related post: Clarient Deal Frees Up Cash for Safeguard Scientifics
Categories: Blog, cancer, COMPANIES, feature2, Member Spotlight
Leave a Reply